This trial is testing a new therapy to see if it can reduce leukemia before a patient gets a bone marrow transplant. The hope is that it will improve the patient's chances of survival.
- B-cell Acute Lymphoblastic Leukemia
- Refractory B Acute Lymphoblastic Leukemia
- Relapsed B-cell Acute Lymphoblastic Leukemia
2 Primary · 1 Secondary · Reporting Duration: 42 Months
Side Effects for
1 Treatment Group
1 of 1
35 Total Participants · 1 Treatment Group
Primary Treatment: Blinatumomab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age < 65 · All Participants · 13 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Could you provide a synopsis of the research that has been done with Blinatumomab?
"As of now, there are 46 clinical trials examining blinatumomab with 9 in phase 3. Although the bulk of these studies take place in Milwaukee, WI, there are 2395 sites conducting this research worldwide." - Anonymous Online Contributor
Has Blinatumomab fulfilled the requirements to obtain FDA approval?
"The safety of Blinatumomab has been evaluated and given a score of 2, as this is only at the Phase 2 stage; no efficacy data yet exists." - Anonymous Online Contributor
Is this trial enrolling participants at the present time?
"The clinical trial is open for enrollment, as indicated by information on the clinicaltrials.gov website. This medical study was initially posted in January 2021 and most recently updated at April 2022." - Anonymous Online Contributor
What is the participant size of this clinical research?
"Affirmative. Clinicaltrials.gov's records demonstrate that this research project is actively seeking participants; it was initially posted on January 1st 2021, and the latest information update occurred April 4th 2022. 35 patients must be recruited from a single site for successful completion of the trial." - Anonymous Online Contributor